Roth Capital Reiterates Buy Rating for Heat Biologics Inc. (HTBX)

roth-capital-reiterates-buy-rating-for-heat-biologics-inc-htbx.gif

Heat Biologics Inc. (NASDAQ:HTBX)‘s stock had its “buy” rating restated by Roth Capital in a note issued to investors on Thursday. They currently have a $2.75 price target on the biopharmaceutical company’s stock. Roth Capital’s price target suggests a potential upside of 96.43% from the stock’s previous close.
Several other research analysts have also recently weighed in on the company. Zacks Investment Research raised Heat Biologics from a “hold” rating to a “buy” rating and set a $1.75 target price for the company in a research note on Friday, August 19th. Noble Financial reaffirmed a “buy” rating and set a $8.00 target price on shares of Heat Biologics in a research note on Wednesday, August 17th. Five investment analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and an average price target of $6.38.
Heat Biologics (NASDAQ:HTBX) traded down 2.14% on Thursday, hitting $1.37. The stock had a trading volume of 185,692 shares. The company’s market cap is $26.70 million. Heat Biologics has a one year low of $0.40 and a one year high of $5.89. The stock has a 50-day moving average of $1.39 and a 200-day moving average of $0.87.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/15/roth-capital-reiterates-buy-rating-for-heat-biologics-inc-htbx.html

Heat Biologics (NASDAQ:HTBX) last released its quarterly earnings results on Monday, August 15th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.27) by $0.10. Equities analysts expect that Heat Biologics will post ($0.76) earnings per share for the current fiscal year.
An institutional investor recently raised its position in Heat Biologics stock. Sabby Management LLC boosted its position in Heat Biologics Inc. (NASDAQ:HTBX) by 4,005.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 902,007 shares of the biopharmaceutical company’s stock after buying an additional 880,036 shares during the period. Sabby Management LLC owned 10.71% of Heat Biologics worth $626,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 8.63% of the company’s stock.
Heat Biologics Company Profile
Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).

Receive News & Ratings for Heat Biologics Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Heat Biologics Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Be the first to comment on "Roth Capital Reiterates Buy Rating for Heat Biologics Inc. (HTBX)"

Leave a comment

Your email address will not be published.

*